<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03764072</url>
  </required_header>
  <id_info>
    <org_study_id>VX18-150-104</org_study_id>
    <nct_id>NCT03764072</nct_id>
  </id_info>
  <brief_title>A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy</brief_title>
  <official_title>A Phase 2B Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-150 for Acute Pain Following Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the dose-response relationship and safety of VX-150 in treating
      acute pain following bunionectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Actual">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">January 17, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-weighted Sum of Pain Intensity Difference Between VX-150 Versus Placebo as Recorded on Numeric Pain Rating Scale (NPRS) 0 to 24 Hours (SPID24) After First Dose</measure>
    <time_frame>0 to 24 hours after first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-weighted Sum of Pain Intensity Difference Between VX-150 Versus Placebo as Recorded on Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After First Dose</measure>
    <time_frame>0 to 48 hours after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With at Least 30 Percent (%), 50%, or 70% Reduction in NPRS at 24 Hours After First Dose of VX-150 Versus Placebo</measure>
    <time_frame>24 hours after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of &quot;Confirmed Perceptible Pain Relief&quot; and &quot;Meaningful Pain Relief&quot; After First Dose of VX-150 Versus Placebo</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic Parameters of VRT-1207355 (Active Moiety) and Metabolite M5: Cmax</measure>
    <time_frame>pre-dose up to 12 hours after the last dose on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic Parameters of VRT-1207355 (Active Moiety) and Metabolite M5: AUC</measure>
    <time_frame>pre-dose up to 12 hours after the last dose on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Assessed by Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From signing of informed consent form to safety follow-up, up to 9 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>VX-150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-150</intervention_name>
    <description>Multiple doses for VX-150 will be administrated orally.</description>
    <arm_group_label>VX-150</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo matched to VX-150 orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Before surgery:

          -  Body mass index (BMI) of 18.0 to 38.0 kilogram per meter square (kg/m^2)

          -  Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair,
             without collateral procedures, under regional anesthesia (Mayo and popliteal sciatic
             block) not to include base wedge procedure

        After surgery:

          -  Subject reported pain of greater than or equal to (&gt;=) 4 on Numeric Pain Rating Scale
             (NPRS) and moderate or severe pain on the Verbal Categorical Rating Scale (VRS) within
             9 hours after removal of the popliteal sciatic block on Day 1

          -  Subject is lucid and able to follow commands

          -  All analgesic guidelines were followed during and after the bunionectomy

        Key Exclusion Criteria:

        Before surgery:

          -  History in the past 10 years of malignancy, except for squamous cell skin cancer,
             basal cell skin cancer, and Stage 0 cervical carcinoma in situ

          -  History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)

          -  History of abnormal laboratory results &gt;=2.5*upper limit of normal (ULN)

          -  History of peripheral neuropathy

          -  A known or clinically suspected infection with human immunodeficiency virus or
             hepatitis B or C viruses

          -  Prior medical history of bunionectomy or other foot surgery on the index foot

          -  History of peptic ulcer disease, or intolerance or unwillingness to receive ibuprofen

        After surgery:

          -  Subject had a type 3 deformity requiring a base wedge osteotomy or concomitant surgery

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <disposition_first_submitted>January 17, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 17, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 27, 2020</disposition_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

